Literature DB >> 14508111

CD95 rapidly clusters in cells of diverse origins.

Jessica C Fanzo1, Maureen P Lynch, Hyewon Phee, Marc Hyer, Aida Cremesti, Heike Grassme, James S Norris, K Mark Coggeshall, Bo R Rueda, Alessandra B Pernis, Richard Kolesnick, Erich Gulbins.   

Abstract

We have shown that CD95-mediated cell death requires a clustering of the receptor in distinct sphingolipid-rich domains of the cell membrane (Grassme et al., 2000, Cremesti et al., 2000). These domains form in response to acid sphingomyelinase (ASM)-induced ceramide generation. However, recent studies challenged the finding of early CD95 clustering (Algeciras-Schimnich et al., 2002). Here, six independent groups tested clustering of CD95 in diverse cell type including primary cells ex vivo and established cell lines. The studies show clustering of CD95 within seconds to minutes in all cell types tested by the different groups. In addition, clustering of CD95 was detected after stimulation of cells using three agonistic anti-CD95 antibodies (CH11, APO-1-3 and JO2), CD95 ligand and stimuli that induce an upregulation and activation of the endogenous CD95/CD95 ligand system. The data confirm our previous studies and suggest rapid, i.e., within seconds to minutes, CD95 clustering as a general phenomenon occurring in many cell types.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508111     DOI: 10.4161/cbt.2.4.442

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  12 in total

Review 1.  Ion channels and membrane rafts in apoptosis.

Authors:  I Szabò; C Adams; E Gulbins
Journal:  Pflugers Arch       Date:  2004-04-08       Impact factor: 3.657

Review 2.  Ceramide-rich platforms in transmembrane signaling.

Authors:  Branka Stancevic; Richard Kolesnick
Journal:  FEBS Lett       Date:  2010-02-20       Impact factor: 4.124

Review 3.  Sphingolipids and lipid rafts: Novel concepts and methods of analysis.

Authors:  Erhard Bieberich
Journal:  Chem Phys Lipids       Date:  2018-09-05       Impact factor: 3.329

4.  Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

Authors:  Hyunki Kim; Guihua Zhai; Sharon L Samuel; Christopher J Rigell; Heidi R Umphrey; Samir Rana; Cecil R Stockard; Naomi S Fineberg; Kurt R Zinn
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

Review 5.  Non-pharmacological factors that determine drug use and addiction.

Authors:  Serge H Ahmed; Aldo Badiani; Klaus A Miczek; Christian P Müller
Journal:  Neurosci Biobehav Rev       Date:  2018-09-01       Impact factor: 8.989

6.  Caspase-8 and caspase-7 sequentially mediate proteolytic activation of acid sphingomyelinase in TNF-R1 receptosomes.

Authors:  Bärbel Edelmann; Uwe Bertsch; Vladimir Tchikov; Supandi Winoto-Morbach; Cristiana Perrotta; Marten Jakob; Sabine Adam-Klages; Dieter Kabelitz; Stefan Schütze
Journal:  EMBO J       Date:  2010-12-14       Impact factor: 11.598

7.  Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.

Authors:  Hyunki Kim; Sharon L Samuel; Guihua Zhai; Samir Rana; Marie Taylor; Heidi R Umphrey; Denise K Oelschlager; Donald J Buchsbaum; Kurt R Zinn
Journal:  Cancer Biol Ther       Date:  2014-08       Impact factor: 4.742

8.  Acid sphingomyelinase involvement in tumor necrosis factor alpha-regulated vascular and steroid disruption during luteolysis in vivo.

Authors:  Luiz E Henkes; Brian T Sullivan; Maureen P Lynch; Richard Kolesnick; Danielle Arsenault; Mark Puder; John S Davis; Bo R Rueda
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-27       Impact factor: 11.205

Review 9.  Ceramide, membrane rafts and infections.

Authors:  Erich Gulbins; Stephan Dreschers; Barbara Wilker; Heike Grassmé
Journal:  J Mol Med (Berl)       Date:  2004-04-07       Impact factor: 4.599

10.  Recruitment of the adaptor protein Grb2 to EGFR tetramers.

Authors:  Noga Kozer; Dipak Barua; Christine Henderson; Edouard C Nice; Antony W Burgess; William S Hlavacek; Andrew H A Clayton
Journal:  Biochemistry       Date:  2014-04-21       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.